Please try another search
For the fiscal year ended 31 December 2021, SR Biotek Inc revenues increased from W1.69B to W5.68B. Net loss decreased 59% to W545.7M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Commission Paid decrease of 10% to W308.8M (expense), Rental Expense decrease of 77% to W4.5M (expense), Interest Expense decrease of 27% to W32.1M (expense).
Period Ending: | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
---|---|---|---|---|
Total Revenue | 5681.25 | 1685.38 | 1219.13 | 1004.13 |
Gross Profit | 969.73 | 5.83 | 221.01 | 264.18 |
Operating Income | -394.07 | -1204.46 | -515.59 | -904.71 |
Net Income | -545.66 | -1335.93 | -694.53 | -1009.78 |
Period Ending: | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
---|---|---|---|---|
Total Assets | 2567.63 | 1825.05 | 1982.99 | 2749.27 |
Total Liabilities | 2868.63 | 1636.11 | 1979.8 | 2051.52 |
Total Equity | -301 | 188.93 | 3.2 | 697.76 |
Period Ending: | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
---|---|---|---|---|
Period Length: | 12 Months | 12 Months | 12 Months | 12 Months |
Cash From Operating Activities | 317.81 | -1154.13 | -496.08 | -842.7 |
Cash From Investing Activities | -60.36 | -78.6 | 1.11 | -22.01 |
Cash From Financing Activities | -199 | 1190.84 | -55.92 | 678.49 |
Net Change in Cash | 17.32 | -41.89 | -550.89 | -186.22 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review